Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: AM833 · NNC0174-0833
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Amylin analogue peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Amylin-related satiety signaling; distinct from GLP-1 agonism.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Amylin analogue offered alone or in CagriSema; keep the interventions separate.
Human evidence
REDEFINE-1 included cagrilintide, semaglutide, combination and placebo arms. Combination results cannot be assigned to cagrilintide alone.
Preclinical evidence
Satiety mechanisms motivate combination research, not DIY equivalence.
Critical reading and limitations
Combination evidence does not quantify each standalone vial effect or validate premixed products.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
2.4 mg · Study-arm target amount
- Frequency
- Weekly
- Duration
- 68 weeks
- Route
- Subcutaneous
- Context
- Cagrilintide-only arm and CagriSema component studied separately. Not a mixing recipe.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID40544433 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
US: FDA unapproved-GLP-1 notice also identifies cagrilintide as unapproved; do not infer approval from a phase III publication.
Adverse effects and unknowns
GI tolerability is clinically relevant; long-term and unstudied combination risks remain uncertain.
GI burden and treatment discontinuation matter alongside weight change.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID40544433 · Randomized controlled trial
Adults without diabetes; four groups.
Weekly SC, 68 weeks.
CagriSema −20.4% versus −3.0% with placebo; individual arms included.
An exact-combination trial does not validate other cagrilintide stacks, supplier blends or the same synergy.
n = 3417
Trials attributed in the package
NCT05567796 · A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightRegistry status: Active, not recruitingLast update posted: September 30, 2026Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Cagrilintide · 44 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07220759 · Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideRegistry status: Active, not recruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT07564414 · A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRegistry status: RecruitingLast update posted: September 30, 2026Query verification: October 16, 2026
NCT07253285 · A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRegistry status: RecruitingLast update posted: September 30, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID40544433
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group.
October 16, 2026
- R30
- SEARCH-PUBMED-cagrilintide
PubMed/MED targeted search: TITLE:"cagrilintide" AND TITLE:phase
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026